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Accumulating evidence confirms different patterns of
HIV-associated cancers in developed and developing
countries. We report results of risk for specific cancers
associated with HIV-1 infection from an on-going case
control study started in government hospitals in Johan-
nesburg in 1995.
Cases consisted of cancers known or suspected to be asso-
ciated with HIV infection: Kaposi sarcoma (n = 333),
Non-Hodgkin lymphoma (n = 223), cancer of the uterine
cervix (n = 1586), Hodgkin lymphoma (n = 154), cancers
of anogenital organs other than cervix (n = 157), squa-
mous cell skin cancer (n = 70), oral cavity and pharyngeal
cancers (n = 319), liver cancer (n = 83), stomach cancer (n
= 142), leukaemias (n = 323), myelomas (n = 189),
melanoma (n = 53), lung cancer (n = 363) and sarcomas
other than Kaposi (n = 93).
The comparison group comprised 3,717 patients with all
other cancer types and 682 patients with cardiovascular
diseases.
Odds Ratios (OR) were adjusted for age, sex, year of diag-
nosis, education level and number of sexual partners.
Significantly increased risks associated with HIV-1 infec-
tion were found for Kaposi sarcoma (OR = 47.1, 95% CI
= 31.9 – 69.8), Non-Hodgkin lymphoma (OR = 5.9, 95%
CI = 4.3 – 8.1), cancer of the cervix (OR = 1.6, 95% CI =
1.3 – 2.0), Hodgkin lymphoma (OR = 1.6, 95% CI = 1.0
– 2.7), cancers of anogenital organs other than cervix (OR
= 2.2, 95% CI = 1.4 – 3.3) and squamous cell skin cancers
(OR = 2.6, 95% CI = 1.4 – 4.9).
Our study results are supported by data from the pathol-
ogy-based South African National Cancer Registry. In
2001 Kaposi sarcoma was recorded as the leading cancer
in black males age 20 to 44 and in black females aged 20
to 29. From age 30, cervical cancers was the most com-
mon cancer diagnosed in black women.
The above figures reflect HIV-related cancers prior to the
public health sector roll-out of ART (anti-retroviral ther-
apy), which began in 2005.
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